These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 2936443)

  • 1. Clinical study of a new antimetastatic compound, Nafazatrom (Bay g 6575). Effects on platelet consumption and monocyte prostaglandin production in patients with advanced cancer.
    Warrell RP; Bockman RS; Staszewski H; Maiese K
    Cancer; 1986 Apr; 57(8):1455-60. PubMed ID: 2936443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A clinical trial of nafazatrom (Bay g 6575) in advanced cancer.
    O'Donnell JF; Blakowski SA; Zacharski LR; Nierenberg DW; Coughlin CT; Fein S; Philipp E; Cornwell GG
    Am J Clin Oncol; 1986 Apr; 9(2):152-5. PubMed ID: 3717082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo and in vitro effects of nafazatrom (Bay g 6575), an antithrombotic compound, on arachidonic acid metabolism in platelets and vascular tissue.
    Fischer S; Struppler M; Weber PC
    Biochem Pharmacol; 1983 Jul; 32(14):2231-6. PubMed ID: 6688182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I clinical study of nafazatrom.
    Hortobagyi GN; Papadoupoulos NE; Frye D; Ajani J; Reuben JM
    Invest New Drugs; 1986; 4(3):251-5. PubMed ID: 3818230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of nafazatrom on platelet function and release: relationship to symptomatic episodes in patients with peripheral vascular disease.
    Buchanan MR; Butt RW; Turpie AG
    Am Heart J; 1987 May; 113(5):1133-7. PubMed ID: 2953219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of efficacy of nafazatrom, a novel anti-thrombotic compound, in patients with coronary artery disease.
    Roy L; Mehta J; Mehta P
    Am Heart J; 1985 May; 109(5 Pt 1):1026-31. PubMed ID: 3158183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug treatments for metastasis of the Lewis lung carcinoma: lack of correlation between inhibition of lung metastasis and survival.
    Merriman RL; Shackelford KA; Tanzer LR; Campbell JB; Bemis KG; Matsumoto K
    Cancer Res; 1989 Aug; 49(16):4509-16. PubMed ID: 2743339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A clinical study of nafazatrom in advanced human breast cancer.
    Jones AL; Powles TJ; Forgeson GV; Coombes RC
    Cancer Chemother Pharmacol; 1991; 27(4):326-8. PubMed ID: 1998990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interference with tumor cell-induced degradation of endothelial matrix on the antimetastatic action of nafazatrom.
    Maniglia CA; Loulakis PP; Sartorelli AC
    J Natl Cancer Inst; 1986 Apr; 76(4):739-44. PubMed ID: 3457206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of arterial thrombosis and platelet function by nafazatrom.
    Buchanan MR; Blajchman M; Hirsh J
    Thromb Res; 1982 Oct; 28(2):157-70. PubMed ID: 6758186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I and pharmacologic evaluation of nafazatrom in patients with cancer.
    Haas CD; Baker LH; Evans LJ
    Invest New Drugs; 1984; 2(1):13-7. PubMed ID: 6469495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nafazatrom (Bay g-6575), an antithrombotic and antimetastatic agent, inhibits 15-hydroxyprostaglandin dehydrogenase.
    Wong PY; Chao PH; McGiff JC
    J Pharmacol Exp Ther; 1982 Dec; 223(3):757-60. PubMed ID: 6754908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study of platelet aggregation in vivo. IX. Effect of nafazatrom on in vivo platelet aggregation and spontaneous tumor metastasis.
    Ambrus JL; Ambrus CM; Gastpar H; Williams P
    J Med; 1982; 13(1-2):35-47. PubMed ID: 6288824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival of mice with NC carcinoma is unchanged by drugs that are thought to inhibit thromboxane synthesis or increase prostacyclin formation.
    Stamford IF; Melhuish PB; Carroll MA; Corrigan CJ; Patel S; Bennett A
    Br J Cancer; 1986 Aug; 54(2):257-63. PubMed ID: 3755610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nafazatrom-induced salvage of ischemic myocardium in anesthetized dogs is mediated through inhibition of neutrophil function.
    Bednar M; Smith B; Pinto A; Mullane KM
    Circ Res; 1985 Jul; 57(1):131-41. PubMed ID: 2988818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism of the stimulation of prostaglandin H synthase and prostacyclin synthase by the antithrombotic and antimetastatic agent, nafazatrom.
    Marnett LJ; Siedlik PH; Ochs RC; Pagels WR; Das M; Honn KV; Warnock RH; Tainer BE; Eling TE
    Mol Pharmacol; 1984 Sep; 26(2):328-35. PubMed ID: 6434940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nafazatrom (Bay g 6575) blunts canine hypoxic pulmonary vasoconstriction: evidence for a prostaglandin-mediated mechanism.
    Ensley RD; Rubin LJ
    Prostaglandins Leukot Med; 1985 Apr; 18(1):95-104. PubMed ID: 3923499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nafazatrom (BAY g 6575), a potent stimulator of prostacyclin release from cardiac and renal vessel wall.
    Klitzke AK
    Arch Int Pharmacodyn Ther; 1984 Oct; 271(2):220-8. PubMed ID: 6391401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of leukotriene B4 formation in human neutrophils after oral nafazatrom (Bay g 6575).
    Strasser T; Fischer S; Weber PC
    Biochem Pharmacol; 1985 Jun; 34(11):1891-4. PubMed ID: 2988560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reaction of the antithrombotic and antimetastatic agent, nafazatrom, with oxidizing radicals.
    Sevilla MD; Neta P; Marnett LJ
    Biochem Biophys Res Commun; 1983 Sep; 115(3):800-6. PubMed ID: 6312995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.